1 Guidance

1 Guidance

1.1 Aflibercept solution for injection is recommended as an option for treating visual impairment caused by diabetic macular oedema only if:

  • the eye has a central retinal thickness of 400¬†micrometres or more at the start of treatment and

  • the company provides aflibercept with the discount agreed in the patient access scheme.

1.2 People whose treatment with aflibercept is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue aflibercept until they and their NHS clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)